Bioxydyn offers MRI measurement of liver transporter fluxes using dynamic contrast-enhanced MRI (DCE-MRI) and proton density fat fraction measurements (MR-PDFF) in the investigation of liver disease, including NASH.
As the lead commercial partner in the IMI TRISTAN project that is investigating the liver and lung toxicity of many drugs in use today with the goal of validating the use of imaging biomarkers to assess and predict the toxicity of potential medicines on the liver and lungs.
Tadimalla S, Wilson DJ, Shelley D, Bainbridge G, Saysell M, Mendichovszky IA, Graves MJ, Guthrie JA, Waterton JC, Parker GJM, Sourbron SP, Bias, Repeatability and Reproducibility of Liver T1 Mapping With Variable Flip Angles. J Magn Reson Imaging. 2022 Feb 27;:.
Waterton JC, Survey of water proton longitudinal relaxation in liver in vivo. MAGMA. 2021 Dec;34(6):779-789.
Berks M, Little RA, Watson Y, Cheung S, Datta A, O'Connor JPB, Scaramuzza D, Parker GJM, A model selection framework to quantify microvascular liver function in gadoxetate-enhanced MRI: Application to healthy liver, diseased tissue, and hepatocellular carcinoma. Magn Reson Med. 2021 Oct;86(4):1829-1844.
Ulloa JL, Stahl S, Yates J, Woodhouse N, Kenna JG, Jones HB, Waterton JC, Hockings PD, Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. NMR Biomed. 2013 Oct;26(10):1258-70.
Banerji A, Naish JH, Watson Y, Jayson GC, Buonaccorsi GA, Parker GJ, DCE-MRI model selection for investigating disruption of microvascular function in livers with metastatic disease. J Magn Reson Imaging. 2012 Jan;35(1):196-203.